ライフサイエンスコーパス: SXR

1 SXR forms a heterodimer with RXR that can bind to and in

2 SXR functions as a xenobiotic sensor to coordinately reg

3 lated antineoplastic agent, did not activate SXR and displayed superior pharmacokinetic properties.

4 re weaker (saquinavir) or unable to activate SXR (nelfinavir, indinavir) thus defining analogs that f

5 monly used chemotherapeutic agent, activated SXR and enhanced P-glycoprotein-mediated drug clearance.

6 therapeutic agent that effectively activates SXR.

7 e to the wide variety of drugs that are also SXR agonists.

8 Two new nuclear hormone receptors, PXR and SXR, have been identified.

9 immunosuppressant effects of xenobiotics and SXR-responsive drugs.

10 thereby demonstrating a direct link between SXR and drug-mediated antagonism of NF-kappaB.

11 rus (HIV) protease inhibitor ritonavir binds SXR and activates its target genes.

12 toward steroids or xenobiotics exhibited by SXR/PXR.

13 to activate CYP3A through previously defined SXR/PXR response elements.

14 nes whereas inhibition of NF-kappaB enhances SXR activity.

15 Therefore, we establish SXR and PXR as bile acid receptors and a role for the xe

16 gene, CYP3A4, identifying it as a bona fide SXR ligand.

17 dentified naturally occurring antagonist for SXR (hPXR).

18 o displace transcriptional corepressors from SXR.

19 t that SFN is a specific antagonist of human SXR and that it inhibits SXR-mediated induction of drug

20 r) thus defining analogs that fail to induce SXR-regulated clearance pathways.

21 SFN can bind directly to SXR, inhibit SXR coactivator recruitment, and efficiently repress SXR

22 Furthermore, SFN inhibited SXR-mediated CYP3A4 expression and CYP3A4-catalyzed mida

23 antagonist of human SXR and that it inhibits SXR-mediated induction of drug clearance.

24 , NF-kappaB activation reciprocally inhibits SXR and its target genes whereas inhibition of NF-kappaB

25 Instead, SXR inhibited VDR-mediated CYP24 promoter activity, and

26 nhibitors are distinct from previously known SXR ligands in that they are peptide mimetic compounds.

27 The known SXR activators rifampicin and hyperforin induced this pa

28 eparture from FXL to FXR (and apparently not SXR) is significant in only the malignant tumors, presum

29 However, here we showed that activation of SXR did not induce CYP24 expression in vitro and in vivo

30 ansgenic animals, we show that activation of SXR/PXR is necessary and sufficient to both induce CYP3A

31 demonstrate how the molecular activities of SXR can be manipulated to control drug clearance.

32 In transgenic mice, an activated form of SXR causes constitutive upregulation of CYP3A gene expre

33 1 transcription by acting as an inhibitor of SXR.

34 ery low in tissues containing high levels of SXR, including the small intestine.

35 have important implications for the role of SXR in regulating drug clearance and hepatic disorders a

36 hment in liver and intestine, major sites of SXR/PXR expression that are critical in xenobiotic metab

37 This expands the ligand specificity of SXR to include this unique chemical class whose pharmace

38 implication of this work is that a subset of SXR activators may function as effective therapeutic age

39 o the wide range of xenobiotics that are PXR/SXR ligands, including drugs, dietary constituents, and

40 rs that is consistent with activation of PXR/SXR by bile acids.

41 eceptor/steroid and xenobiotic receptor (PXR/SXR) closely paralleled each other but was markedly diff

42 to and activated the orphan nuclear receptor SXR and induced expression of the SXR target gene, CYP3A

43 The orphan nuclear receptor SXR coordinately regulates drug clearance in response to

44 Nuclear receptor SXR/PXR (steroid and xenobiotic receptor/pregnenolone X

45 monstrate that the human xenobiotic receptor SXR (steroid and xenobiotic receptor) and its rodent hom

46 tivation of steroid and xenobiotic receptor (SXR) also enhances the expression of CYP24, providing a

47 clear receptors steroid xenobiotic receptor (SXR) and the constitutive active receptor, CAR.

48 the nuclear steroid and xenobiotic receptor (SXR) by commonly used drugs in humans inhibits the activ

49 termed the steroid and xenobiotic receptor (SXR), which activates transcription in response to a div

50 ated by the steroid and xenobiotic receptor (SXR).

51 homologue, steroid and xenobiotic receptor (SXR).

52 e receptor, steroid and xenobiotic receptor (SXR; also called "hPXR").

53 e mammalian steroid and xenobiotic receptor, SXR/PXR.

54 m could enter even the slow-exchange-regime (SXR).

55 tivator recruitment, and efficiently repress SXR activities.

56 ne, the pregnane X receptor (PXR in rodents, SXR in humans), regulates p-glycoprotein expression.

57 We conclude that SXR/PXR genes encode the primary species-specific xeno-s

58 Unexpectedly, we found that SXR can regulate CYP2B, both in cultured cells and in tr

59 We show here that SXR also regulates drug efflux by activating expression

60 ver and intestine, our results indicate that SXR has a dual role in mediating vitamin D catabolism an

61 Finally, we show that SXR ligands activate expression of multiple resistance p

62 in cells isolated from mice deficient in the SXR ortholog PXR.

63 significantly increased in mice lacking the SXR ortholog pregnane X receptor (PXR), thereby demonstr

64 expression was enhanced in mice lacking the SXR ortholog pregnane X receptor, and treatment of human

65 r receptor SXR and induced expression of the SXR target gene, CYP3A4, identifying it as a bona fide S

66 X receptor, and treatment of humans with the SXR agonist rifampicin had no effect on intestinal CYP24

67 This SXR/PXR-NF-kappaB axis provides a molecular explanation

68 tor of bone-specific genes that acts through SXR to favor the expression of osteoblastic markers.

69 Thus, SXR has a novel role as a mediator of bone homeostasis i

70 SFN can bind directly to SXR, inhibit SXR coactivator recruitment, and efficientl